Inhibition of BACE‐1 by low‐molecular‐weight compounds has emerged as a new concept for treatment of AD (Vassar et al, 2014; Eketjall et al, 2016; Kennedy et al, 2016; Timmers et al, 2016, 2017; Yan et al, 2016; Cebers et al, 2017) by preventing the generation and deposition of Aβ rather than just treating the dementia symptoms. This evidence concerns the gene BACE1 and Alzheimer disease.